Novan continues to recruit, adds dermatology advisory council
On the heels of wooing former Quintiles executive Paula Brown Stafford to serve as the company ’s chief development officer, Novan (Nasdaq: NOVN) has recruited an eight-member dermatology advisory council.
Novan recently announced an update on development plans for its lead candidate for the treatment of acne, SB204. The company stated that it is planning a presubmission meeting with the U .S. Food and Drug Administration for SB204 in the third quarter of 2017, which could result in a new drug application…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Jennifer Henderson Source Type: news
More News: Acne | Biotechnology | Dermatology | Food and Drug Administration (FDA) | Health Management | Skin